ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, November 5, 4:30 PM ESTDial-In: ...

Core Insights - electroCore, Inc. announced a peer-reviewed study demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI) [1][2] - The study found that adjunctive use of gammaCore with standard care led to significant improvements in multiple domains of the Neurobehavioral Symptom Inventory (NSI) [2][4] - Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms, with significant reductions observed in 16 of 22 symptom categories [8] Study Details - The study included 102 patients with persistent symptoms following mTBI, showing improvements in both early and late treatment groups [3][8] - No device-related adverse events were reported, indicating a favorable safety profile for the nVNS treatment [3] - The findings are particularly relevant for the U.S. military, where 1-2% of service members experience mild TBI annually [2] Company Overview - electroCore is a commercial-stage bioelectronic technology company focused on improving health through innovative non-invasive technologies [5] - The company's leading products include gammaCore nVNS and Quell neurostimulator, which treat chronic pain syndromes [5]

ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical ...

Company Leadership Changes - Peter Cuneo has departed from the Board of Directors of electroCore, Inc., with Thomas J. Errico, MD, elected as the new Chairman of the Board effective September 2, 2025 [1][2] - Cuneo will continue to serve as a strategic advisor to the company [1] - CEO Dan Goldberger expressed gratitude for Cuneo's contributions since 2020, highlighting his role in the company's turnaround [2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [3] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Insights - electroCore, Inc. has partnered with former NFL player Greg Buttle to promote its Truvaga™ Plus device, which is designed for vagus nerve stimulation to enhance relaxation, clarity, and sleep quality [1][4] - Truvaga Plus is a handheld device that utilizes bioelectronic technology to stimulate the vagus nerve, helping users transition from stress to a balanced state [3][8] - The partnership will include radio spots and digital campaigns aimed at raising awareness about stress management and the benefits of Truvaga Plus [4] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive technologies [6] - The company offers products like gammaCore and Quell, which treat chronic pain, alongside Truvaga and TAC-STIM for general wellness [6] - Truvaga Plus is backed by over 20 years of research in bioelectronic medicine and is intended for general health and wellness purposes [5][8]

Core Insights - electroCore, Inc. has appointed Elena Bonfiglioli to its Board of Directors effective September 2, 2025, following the retirement of Peter Cuneo [1] - Ms. Bonfiglioli brings over two decades of experience in the healthcare sector, currently serving as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and International clinical applications [2] - She has been recognized as one of the top 50 AI Innovators and has held various leadership roles in healthcare organizations, emphasizing the use of data and AI to enhance health outcomes [2][3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [4] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [4] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [4]

Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [3] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, and Quell neurostimulator, both aimed at treating chronic pain syndromes through non-invasive neuromodulation technology [3] - Additionally, electroCore offers handheld and personal use products such as Truvaga and TAC-STIM nVNS, which utilize bioelectronic technologies to promote general wellness and human performance [3] Upcoming Events - Management of electroCore will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at the Lotte New York Palace Hotel [1] - One-on-one meetings will be hosted throughout the day for interested investors [1] Investor Relations - Investors wishing to request a meeting can contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations via email at ecor@fnkir.com [2]

Company Overview - electroCore is a commercial-stage bioelectronic medicine and wellness company focused on multiple indications[6] - The company has FDA clearance for the prevention and treatment of primary headache in adults and adolescents[13] - The company has FDA authorization for symptoms of Fibromyalgia[13] Financial Performance and Projections - The company's revenue has a 5-year CAGR of 58%[7] - Revenue increased from $5.5 million in 2021 to $25.2 million in 2024[12] - Revenue is projected to reach $30 million in 2025[12] - Gross margins are approximately 85%[13] Market Opportunity - The total addressable market (TAM) for VA channel is $2.9 billion[15] - The total addressable market (TAM) for US commercial channel is $101 million[15] - The total addressable market (TAM) for Health & Wellness channel is $33 billion[15] - The total addressable market (TAM) for TAC-STIM is $9.7 billion[15] - $20 billion is spent annually out-of-pocket for chronic pain treatments[14]

Core Insights - electroCore, Inc. reported first quarter 2025 net sales of $6.7 million, a 23% increase compared to $5.4 million in the same period of 2024 [3][6] - The company closed the acquisition of NeuroMetrix, which is expected to enhance its position in the non-invasive bioelectronic technology market [2][6] - The CEO highlighted a 29% growth in total revenue excluding TAC-STIM, indicating strong performance in core product lines [2][6] Financial Performance - Gross profit for the first quarter of 2025 was $5.7 million, representing an 85% gross margin, compared to $4.6 million and 84% gross margin in the first quarter of 2024 [4][18] - Total operating expenses increased to approximately $9.5 million from $8.4 million in the first quarter of 2024, driven by higher selling, general, and administrative expenses [5][6] - The GAAP net loss for the first quarter of 2025 was $3.9 million, or a loss of $0.47 per share, compared to a net loss of $3.5 million, or a loss of $0.53 per share, in the first quarter of 2024 [8][18] Revenue Breakdown - Sales of prescription gammaCore to the U.S. Department of Veterans Affairs (VA) reached $4.7 million, a 22% increase from $3.9 million in the prior year [4] - International sales grew by 14%, with total sales outside the United States amounting to $513,000 [4] - Truvaga wellness products saw significant growth, with sales increasing by 187% to $1.1 million compared to $385,000 in the first quarter of 2024 [4] Guidance and Outlook - For the full year 2025, the company expects total revenue to be approximately $30 million, with net cash used for the next three quarters projected between $3.8 million and $4.3 million [12] - The acquisition of NeuroMetrix is anticipated to contribute meaningful revenue by the end of 2025, expanding the company's product offerings [12]